HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...

The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.